Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company developing advanced T-cell therapies for cancer and autoimmune diseases.
The UK Home Office lists Autolus Therapeutics as a licensed sponsor (A-rated, Global Business Mobility: Senior or Specialist Worker and Skilled Worker route). They can sponsor work visas. We read every advert and list only roles that don't rule out sponsorship. Home Office figures released under the Freedom of Information Act show Autolus Therapeutics assigned 14 Certificates of Sponsorship in 2021–24 for Skilled Worker and Global Business Mobility visas. We're showing 2 of their current openings.
Sponsor licence details
Sourced from the UK Home Office register of licensed sponsors.
Sponsorship history
Certificates of Sponsorship Autolus Therapeutics assigned each year, from Home Office figures released under the Freedom of Information Act.
Skilled Worker and Global Business Mobility routes. One certificate is assigned for each sponsored hire, visa extension or change of employer, so a person can be counted more than once. “1–5” is withheld by the Home Office; the 2025 figures list only sponsors with 5 or more (“—”). Matched to this employer by its name on the sponsor register. Sources: FOI 2025/12841 (2021–24), FOI2026/03501 (2025). Contains public sector information licensed under the Open Government Licence v3.0.
About Autolus Therapeutics
Autolus Therapeutics is a healthcare company focused on the development of precisely targeted, controlled, and highly active autologous T-cell therapies. The company utilises advanced cell programming capabilities and chimeric antigen receptors to reprogram a patient's own T-cells, enabling them to recognise and destroy cancer cells.
The company operates its own proprietary viral vector and semi-automated cell manufacturing processes. Its clinical-stage programs target hematological and solid tumor indications, as well as autoimmune diseases.
Open roles
2 live positions matched to this sponsor licence.